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Background: The bacterium Staphylococcus aureus constitutes one of the most important causes of nosocomial
infections. One out of every three individuals naturally carries S. aureus in their anterior nares, and nasal carriage is
associated with a significantly higher infection rate in hospital settings. Nasal carriage can be either persistent or
intermittent, and it is the persistent carriers who, as a group, are at the highest risk of infection and who have the
highest nasal S. aureus cell counts. Prophylactic decolonization of S. aureus from patients’ noses is known to reduce
the incidence of postsurgical infections, and there is a clear rationale for rapid identification of nasal S. aureus
carriers among hospital patients.
Findings: A molecular diagnostic assay was developed which is based on helicase-dependent target amplification
and amplicon detection by chip hybridization to a chip surface, producing a visible readout. Nasal swabs from 70
subjects were used to compare the molecular assay against culturing on “CHROMagar Staph aureus” agar plates.
The overall relative sensitivity was 89%, and the relative specificity was 94%. The sensitivity rose to 100% when
excluding low-count subjects (<100 S. aureus colony-forming units per swab).
Conclusions: This molecular assay is much faster than direct culture and has sensitivity that is appropriate for
identification of high-count (>100 S. aureus colony-forming units per swab) nasal S. aureus carriers who are at
greatest risk for nosocomial infections.
Keywords: Staphylococcus aureus, Nasal carriage, Molecular diagnostic, Helicase-dependent amplificationFindings
Background
Nosocomial bacterial infections are an important cause
of morbidity and mortality, attributable for approxi-
mately 100,000 deaths annually in the United States [1].
The Gram-positive bacterial pathogen Staphylococcus
aureus is causally involved in a significant fraction of
these infections, with about 0.8% of all US hospital inpa-
tients suffering from a S. aureus infection [2]. The anter-
ior nares represent the primary ecological reservoir for
S. aureus in humans, with one in three individuals being
carriers [3]. Three different nasal carriage patterns have
been discerned, with approximately 20% of the popula-
tion being persistent carriers, 30-60% intermittent* Correspondence: bhicke@gbscience.com
Great Basin Corporation, 2441 South 3850 West, Salt Lake City, UT 84120,
USA
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reproduction in any medium, provided the orcarriers, and the remainder being non-carriers [4]. The
quantity of S. aureus colony-forming units (CFU) that
can be recovered from swabs obtained from carriers’
noses varies widely, from single-digits to millions [5,6],
and there is a strong association between high cell count
and persistent carriage [7-9]. Based on various levels of
evidence, it has been suggested that persistent carriers
represent a separate group that is distinct from intermit-
tent and non-carriers [8,10].
Colonization of the human nose by S. aureus repre-
sents a commensal relationship, and carriage is inconse-
quential to the healthy human host in every-day life.
However, S. aureus nasal carriage translates into a three
to four fold higher infection rate in hospital settings
compared to non-carriers [11-14]. In one population of
dialysis patients, persistent nasal S. aureus carriers car-
ried a 3.4 times higher risk than intermittent carriers
[13]. Prospective and retrospective studies revealed thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fer from a S. aureus strain that is clonally identical to
the commensal strain carried in their nose, thereby
strongly implicating an endogenous origin [11,14-16].
Topical intranasal mupirocin application provides an
effective and safe option for S. aureus decolonization
and, when used prophylactically, reduces the incidence
of postsurgical infections [17]. The strongest evidence so
far was provided by a double-blind, placebo-controlled,
multicenter trial that used randomized patient groups
from multiple hospitals in the Netherlands [16]. The
results revealed a 2.4-fold reduction in risk of surgical-
site S. aureus infections for the treatment group. The
authors concluded that rapid identification of nasal S.
aureus carriage at the time of hospital admission speeds
decolonization and is a critical factor in reducing
hospital-associated S. aureus infections. Due to the
reported emergence of mupirocin resistance, it is pru-
dent to restrict nasal mupirocin application only to
patients who are likely to benefit from it [18]. This pro-
vides a strong incentive for hospital-based nasal S. aur-
eus screening of patients who will be undergoing an
invasive medical procedure, by using a molecular diag-
nostic test for rapid identification of nasal carrier status
and initiation of S. aureus decolonization without delay.
Commercially available nasal screening tests generally
use either polymerase chain reaction (PCR)-based or
microbiological culture-based methods. PCR-based mo-
lecular diagnostic tests provide much faster turnaround
relative to the lower cost culture-based methods, and
the benefit of rapid turnaround has been well established
[19]. The commercial PCR assay designs in use identify
methicillin-resistant S. aureus (MRSA) [20-23], and they
do so by targeting a mobile staphylococcal cassette
chromosome (SCC) element referred to as SCCmec [24].
This assay design causes false positive rates that signifi-
cantly impact MRSA screening efficacy [25-27], in par-
ticular in geographic regions where MRSA prevalence is
low or on the decrease, and it can also cause false nega-
tives [28,29]. We have developed an alternative molecu-
lar detection method that targets S. aureus-specific
sequences in the thermonuclease (nuc) gene [30,31].
The assay system recapitulates the rapid turnaround
time of PCR but at lowered cost, using isothermal ampli-
fication coupled to chip-based detection followed by
digital camera capture of the chip image [32].
Subjects, materials and methods
Subjects and nasal swab collection
Subjects who volunteered to provide nasal swabs for this
study were healthy individuals, 39 male and 31 female.
Subjects provided written informed consent for their
nasal swab samples to be utilized in this study, which
was approved by the Great Basin Corporation internalEthics Committee. All samples were de-identified. Each
sterile media-free Double Swab (BD BBL CultureSwabs
220135) was pre-moistened with 75 uL sterile phosphate
buffered saline (PBS) and pre-scored for subsequent
facilitated detachment of the polyester tip from its stem.
Volunteers were instructed to insert the Double Swab
into one of their nostrils and rotate it for at least 15 sec-
onds while scrubbing the surface of the anterior nare,
and then repeat the same procedure for the second nos-
tril. The swabs were kept at ambient temperature and
processed no later than 2 hours after sampling. Swab A
was used for microbiological examination and swab B
was processed for molecular analysis.
Direct culture
The head of swab A was detached from its stem, trans-
ferred into a tube containing 200 uL 10 mM Tris (pH
8.8), 10 mM NaCl (TN-Buffer), and vortexed for 30 sec-
onds at maximum setting. This yielded a recoverable
volume of approximately 160 uL nasal mucus suspen-
sion, and 100 uL thereof was directly plated onto a “BBL
CHROMagar Staph aureus” agar plate (Becton Dicken-
son) which was then incubated at 37°C for 18–20 hours.
The samples that gave rise to mauve colonies on plates,
indicative of S. aureus, were scored as positive by direct
culture. The number of mauve colonies per plate was
counted exactly (if <1000) or estimated (if >1000), and S.
aureus CFU counts per swab were extrapolated by
multiplying with a factor of 1.6.
Preparation of bacterial DNA from nasal swabs
The head of swab B was detached from its stem, placed
into 500 uL TN-Buffer, and vortexed for 30 seconds at
maximum setting. The sample was then centrifuged for
10 minutes at 14,000 x g at ambient temperature. The
supernatant was discarded and the pellet re-suspended
in 100 uL TN-Buffer containing 0.5 U/uL achromopepti-
dase (Wako Chemicals, Richmond, VA). The mixture
was incubated for 15 minutes at 37°C, followed by 5 min-
utes at 98°C. Two 5 uL aliquots were used in replicate
Helicase-dependent amplification reactions, and the rest
was stored frozen at −20°C.
Asymmetric helicase-dependent amplification (HDA)
Amplification reactions were set up according to condi-
tions as provided by the IsoAmp II Universal tHDA Kit
(BioHelix, Beverly, MA). For each individual HDA reac-
tion, 5 uL of nasal mucus lysate was first mixed with 15
μL of Dilution Buffer, giving rise to concentrations of
20 mM Tris–HCl, pH 8.8, 10 mM KCl, 7.7 mM MgSO4,
40 mM NaCl, 5 mg/mL BSA, and 0.02% Tween 20. This
was then added to 20 uL 2x HDA-Mix {20 mM Tris–
HCl, pH 8.8, 40 mM NaCl, 0.02% Triton X-100, 0.4x
EvaGreen (Biotium, Hayward, CA), 6.8 mM dATP,
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uvrD Thermostable DNA Helicase, 1.6 U/uL GST Poly-
merase Large Fragment, 4 ng/uL ET SSB (Extreme
Thermostable Single-Stranded DNA Binding Protein),
and diluted RNase H2 (Great Basin Corp), 600 nM For-
ward primer, and 800 nM biotinylated Reverse primer
(5’ Biotin-TEG)} and mixed thoroughly in a well of a
LightCycler 480 Multiwell Plate 96 (Roche Diagnostics,
Indianapolis, IN). The multiwell plate was transferred
into a LightCycler 480 instrument and incubated for
60 minutes using an isothermal temperature profile set
to 65°C.
Primers were ordered from IDT, and each primer con-
tained a single ribo-nucleotide close to the 3’ end as well as
a 3’ blocking group, creating “hot start-like” conditions.
Deblocking requires that primers be annealed to the target
DNA sequence, resulting in cleavage by RNase H2 at tem-
peratures above 50°C, followed by polymerase extension.
Primer artifact is suppressed because the RNase H2 is
inactive at low temperature. The nucleotide sequences of
the amplification primers were 5’ –TGGTAGAAAAT
GCAAAGAAAATTGAAGTC[rG]AGTT-3’ for the For-
ward primer and 5’- TCCATCAGCATAAATATACG
CTAAGCCA[rC]GTCC-3’ for the Reverse primer, giving
rise to an amplification product size of 95 base pairs.
Chip preparation and hybridization
Crystalline silicon wafers were coated with the polymer
amino functional T-structure poly-dimethylsiloxane
(TSPS, United Chemical Technologies, Bristol, PA) and
cured at 150°C for 24 hours. The TSPS coated wafer was
further prepared by soaking in a 50 mg/L solution of
poly (lys-phe) in 1x phosphate-buffered saline (PBS, pH
6) containing 2 M NaCl overnight at room temperature.
Next, the poly (lys-phe) coated wafer was washed and
soaked in 10 μM succimidyl-4-formyl benzoate (SFB,
Sigma-Aldrich, St. Louis, MO) for 2 hours at room
temperature, washed thoroughly with water, dried with a
stream of nitrogen, and stored at room temperature.
Capture probes were synthesized by IDT and contain
an internal 18-atom hexa-ethyleneglycol spacer con-
nected to a reactive 5’-moiety (I-Linker) that couples to
the aldehyde-functionalized chip surface. Probes in Spot-
ting Buffer (0.1 M phosphate buffer pH 8.0, 10% gly-
cerol) were spotted (75 nL) on the surface of the SFB-
coated silicon wafer. A biotin-labeled [dA]18 detection
control (DC) probe was spotted at 50 nM, and a
hybridization control (HC) capture probe was also spot-
ted at 50 nM (complementary to biotinylated detection
probe present in bybridization buffer). To orient chips
for subsequent processing a fiducial marker (carboxy-
lated polystyrene microspheres) was also printed. The S.
aureus nuc amplicon-specific capture probe was spotted
at 400 nM concentration, and its DNA sequence was5’-GACAAAGGTCAAAGAACTGA-3’. After incubating
for 2 hours, the wafers were washed with 0.1% SDS,
dried, and scribed into individual 6.7 mm square chips
before use.
For chip hybridization, 20 μL of HDA amplicon was
added to 80 μL of hybridization buffer (5x SSC, 0.05%
Tween 20, 0.5% alkaline-treated casein (ATC), 1 nM
hybridization control (HC) biotinylated detection probe)
and pre-warmed in a heat block at 65°C for 5 minutes.
The hybridization mixture was then transferred onto
chips in a 96-well plate that had been prewarmed to 53°
C, and hybridization was allowed to proceed for 5 min-
utes at 53°C. Solution was removed, and the chips were
washed 3 times with WashBuffer-A (0.1x SSC, 0.1%
SDS), then washed 3 times with WashBuffer-B (0.1x
SSC, 0.05% Tween 20), before adding 100 μL of conju-
gate solution (1 μg/mL anti biotin antibody/HRP in 5x
SSC, 10% fetal calf serum, 0.5% ATC) and incubating at
room temperature for 4 minutes. Chips were then washed
3 times with WashBuffer-B before addition of 100 μL Mem-
brane 3,3',5,5'-Tetramethylbenzidine (TMB, BioFX Labora-
tories, Eden Prairie, MN) to the chip surface and incubation
at room temperature for 4 minutes. Chips were washed
with water and methanol, air-dried, and then imaged.
Discrepancy resolution analyses
Nasal swab samples that gave rise to a negative result by
direct culture but a positive result by the molecular
assay were followed up by a repeat of the HDA and chip
hybridization, using fresh aliquots of the original nasal
swab lysates. Furthermore, HDA discordant positives
were followed up by PCR amplification (Roche LightCy-
cler 480) using the nuc gene amplification primers pub-
lished by Brakstad and coworkers [31]. A product band
of the correct size was verified by polyacrylamide gel
electrophoresis. In addition, volunteers whose nasal
swabs produced molecular assay discordant positives
were asked to provide follow-up nasal Double Swabs,
and these were processed as described above for direct
culture as well as molecular assay analysis.
Volunteers whose nasal swabs gave rise to a positive
result by direct culture but a negative result by the mo-
lecular assay, were asked to provide a follow-up nasal
swab a few weeks later. These follow-up swabs were pro-
cessed by direct culturing as described above.
Results and discussion
Analytical assay performance
The molecular diagnostic assay described in this study is
based on isothermal helicase-dependent amplification
(HDA) [33] of Staphylococcus aureus-specific DNA
sequences, derived from the thermonuclease gene nuc,
followed by hybridization of the biotinylated ampli-
fication product to a nuc-specific capture probe
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pooled nasal mucus was spiked with dilutions of S. aur-
eus cells, and the chip could detect as few as 2 CFU per
HDA reaction, which extrapolates to 40 CFU per swab
(data not shown). This indicates that the protocol devel-
oped for this study efficiently enriched and lysed S. aur-
eus cells present in nasal mucus, making the bacterial
genomic DNA available for amplification. A panel of
21 S. aureus strains was then used to test reactivity of
the nuc gene HDA primers and hybridization probe. All
21 strains gave rise to positive HDA and chip
hybridization signals (Table 1). To verify that the assay
detects only Staphylococcus aureus, a panel of prokary-
otic and eukaryotic organisms was examined. No posi-
tive nuc amplicon signal was observed for the 8 other
staphylococcal species or the 17 additional bacterial and
eukaryotic organisms that were tested (Table 2). These
results are consistent with previous studies establishing
that the nuc gene contains S. aureus-specific sequences
[30,31] and with a recently published study in which the
nuc gene was present in 1781 of 1783 S. aureus isolates
(99.9% sensitivity) [34].
S. aureus-positive samples
A total of 70 volunteers were enrolled for this nasal S.
aureus detection study. Of these, 36 individuals wereTable 1 Staphylococcus aureus strains tested for sensitivity of
Organism ATCC number
S. aureus subsp. aureus Rosenbach 6538
S. aureus subsp. aureus Rosenbach 14993
S. aureus subsp. aureus Rosenbach 25923
S. aureus subsp. aureus Rosenbach 33591
S. aureus subsp. aureus Rosenbach 33592
S. aureus subsp. aureus Rosenbach 43300
S. aureus subsp. aureus Rosenbach BAA-1720
S. aureus Rosenbach BAA-1749
S. aureus Rosenbach BAA-1764
S. aureus Rosenbach BAA-1765
S. aureus subsp. aureus Rosenbach BAA-42
S. aureus







S. aureus subsp. aureus MW2
S. aureus
Isolated microbial colonies were suspended in TN-Buffer, lysed by incubation with a
106 cells was added to each HDA molecular assay reaction.culture-positive on “CHROMagar Staph aureus” plates,
with a range between 3 and more than 100,000 CFU per
swab (Table 3). In comparison to direct culture, the mo-
lecular diagnostic assay had a relative sensitivity of 89%
(Table 4). Using a cutoff of 100 S. aureus CFU per swab,
the samples were stratified into “high-count” and “low-
count” groups. This cutoff was selected originally based
on data provided in Figure 2 from the article by Nouwen
et al. [7], which indicated that swabs with more than
100 CFU are significantly more likely to originate from
persistent carriers than from intermittent carriers. More
recently published results revealed that 20/21 samples
from persistent carriers were associated with nasal S.
aureus loads of >100 CFU per swab, and 13/14 samples
from non-persistent carriers were associated with loads
of ≤100 CFU [9], further validating our selection of this
cutoff value. Of the 36 nasal S. aureus carriers identified
in this study, 29 were classified into the high-count group.
All of these 29 individuals were positive by the molecular
assay (Table 3), and for this subgroup the concordance be-
tween the molecular assay and direct culture was 100%
(Table 5). Seven samples had fewer than 100 S. aureus
CFU per swab (Table 3), four of which were negative by
the molecular assay. This is not surprising since these sam-
ples contained S. aureus CFU numbers near or below the
lower limit of detection. Two discrepant samples wereamplification primer set and detection probe
Other designations Molecular assay
FDA 209 positive




















chromopeptidase followed by boiling, and the equivalent of in the order of
Table 2 Species tested for specificity of amplification primer set and detection probe
Organism Source of isolate Characteristics Molecular assay
S. schleiferi ATCC # 43808 Coagulase-positive negative
S. capitis ATCC # 35661 Coagulase-negative negative
S. epidermidis ATCC # 12228 Coagulase-negative negative
S. haemolyticus ATCC # 29970 Coagulase-negative negative
S. hominis ATCC # 700236 Coagulase-negative negative
S. lugdunensis ATCC # 43809 Coagulase-negative negative
S. saprophyticus ATCC # 15305 Coagulase-negative negative
S. succinus ATCC # 700337 Coagulase-negative negative
Bacillus subtilis ATCC # 23859 gram-positive negative
Clostridium difficile ATCC # BAA-1382 gram-positive negative
Enterococcus faecalis ATCC # 700802 gram-positive negative
Enterococcus faecium ATCC # 51559 gram-positive negative
Micrococcus luteus ATCC # 10240 gram-positive negative
Mycobacterium abscessus ATCC # 19977 gram-positive negative
Streptococcus agalactiae ATCC # 13813 gram-positive negative
Streptococcus pneumoniae ATCC # 6308 gram-positive negative
Acinetobacter baumannii ATCC # 17978 gram-negative negative
Citrobacter freundii ATCC # 8090 gram-negative negative
Escherichia coli ATCC # 4157 gram-negative negative
Klebsiella pneumoniae ATCC # 13883 gram-negative negative
Neisseria gonorrhoeae ATCC # 53420 gram-negative negative
Pseudomonas putida ATCC # 47054 gram-negative negative
Candida albicans ATCC # 18804 negative
Saccharomyces cerevisiae Strain S288C negative
Homo sapiens Roche Cat. #11691112001 negative
Isolated microbial colonies were suspended in TN-Buffer (see Materials and Methods section), lysed by incubation with achromopeptidase and/or boiling, and the
equivalent of in the order of 106 cells (or 20 ng purified yeast DNA or 80 ng human DNA) was added to each HDA molecular assay reaction.
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previously published nuc gene primers [31].
Individuals who carry low numbers of S. aureus cells
are more likely to be intermittent rather than persistent
nasal carriers [7-9]. Three volunteers whose nasal swabTable 3 Nasal swab samples giving rise to mauve colonies on
# Initial Swab: CFU/Swab Molecular assay










Samples are sorted by CFU/Swab. The 29 samples giving rise to >100 mauve coloni
CFU: Colony Forming Units. ND: Not Done.samples gave rise to discrepant results (#31, #33, #36,
Table 3) were able to provide a follow-up swab a few
weeks later. Two of the three follow-up swabs turned up
negative on direct culture, classifying these two volunteers
as intermittent S. aureus carriers (#33, #36, Table 3).“CHROMagar S. aureus” agar plates





es per plate were classified as “high-count” and are indicated in bold.




Molecular Assay Positive 32 2 34
Negative 4 32 36
Total 36 34 70
Sensitivity: 89%
Specificity: 94%
Frech et al. BMC Research Notes 2012, 5:430 Page 6 of 8
http://www.biomedcentral.com/1756-0500/5/430S. aureus-negative samples
Of the 70 volunteers, 34 were culture-negative. Two of
these 34 samples gave rise to a positive result by the mo-
lecular assay, which translates into a relative specificity
of 94% (Table 4). Both samples remained positive upon
repeated molecular analysis. Follow-up Double Swabs
were subsequently obtained from the two volunteers.
Swabs from both individuals were again molecular
assay-positive, and individual I was again culture-
negative while individual II yielded 3 CFU, indicating
that individual II was a low-count carrier. The samples
from both volunteers were confirmed as nuc-positive by
PCR analysis [31].
Resolution of the discrepancies between the identification
of S. aureus by nuc gene amplification versus direct micro-
biological culture will require further analyses. While the
microbiological method chosen for this study, direct cultur-
ing on “CHROMagar Staph aureus” chromogenic medium,
is characterized by its simplicity as well as excellent specifi-
city, the sensitivity of this method is not 100%. Among
310 S. aureus-positive clinical specimens, CHROMagar
Staph aureus was 95.5% sensitive [35]. Therefore, one
would expect one or two of the 34 negative samples in the
present study to be falsely negative. Alternatively, it is con-
ceivable that swabs obtained from certain low-count indivi-
duals may contain mostly dead cells that would go
undetected by culture, since this method relies upon the
presence of live cells. Discrepancy resolution might be
achieved by the amplification and sequencing of the rpoB
gene which allows for accurate differentiation of staphylo-
coccal isolates at the species and subspecies level [36].
However, since the nasal environment is known to contain
a mixture of multiple bacterial species [37], sequencing of
amplification products obtained from nasal swab lysatesTable 5 Stratification of S. aureus-positive samples:
high-count group only (>100 CFU/swab)
Number of samples
Positives Negatives
Direct Culture 29 0
Molecular Assay 29 0
Concordance: 100%would require sequence analysis of large numbers of
clones.Prevalence of S. aureus nasal carriage
The fraction of volunteers in this study who were positive
for nasal carriage of S. aureus (36-38/70; 51-54%) is higher
than the 32% prevalence that was reported by the large
(~10,000 subjects) US National Health and Nutrition
Examination Survey conducted between 2001 and 2002 [3].
Notably, nasal S. aureus carriage clusters in families [38],
and the higher prevalence observed in the present study
could be explained by the fact that the volunteer group did
not represent a random population sample but contained a
significant number of biological relatives. Furthermore, the
volunteer group for this study contained more males than
females, and the S. aureus nasal carriage prevalence is
higher among males than females [3]. In addition, the dry
climate in Utah, where this study was conducted, is asso-
ciated with higher rates of nose bleeding which is correlated
with nasal S. aureus carriage [39] and appears to be directly
mediated by the presence of hemoglobin [40].Conclusions
The molecular diagnostic assay described in this study
combines helicase-dependent isothermal amplification of a
S. aureus species-specific DNA sequence out of nasal swab
lysate with chip-based detection by hybridization and an
eye-visible readout. In the present study involving nasal
swabs from 70 volunteers, this molecular assay showed
100% sensitivity in identifying those individuals who are
high-count nasal carriers of S. aureus (>100 CFU per swab).
It is these individuals who have increased risk of infection
after invasive procedures in hospitals, and therefore need to
be rapidly identified and de-colonized prior to an invasive
procedure. The assay concept presented here lends itself to
incorporation into an automated molecular diagnostic plat-
form for rapid identification of nasal S. aureus carriers in
hospital settings.
Updated commercial PCR strategies can incorporate
mecA gene amplification to mitigate the problem of false
positive results in so-called "empty cassette" strains that
result from incomplete SCCmec cassette excision
(Arbefeville SS et al 2012. J Clin Micro 49:2996-2999).
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